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Soluble LR11/SorLA represses thermogenesis in
adipose tissue and correlates with BMI in humans
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Thermogenesis in brown adipose tissue (BAT) is an important component of energy
expenditure in mammals. Recent studies have conﬁrmed its presence and metabolic role in
humans. Deﬁning the physiological regulation of BAT is therefore of great importance for
developing strategies to treat metabolic diseases. Here we show that the soluble form of the
low-density lipoprotein receptor relative, LR11/SorLA (sLR11), suppresses thermogenesis in
adipose tissue in a cell-autonomous manner. Mice lacking LR11 are protected from
diet-induced obesity associated with an increased browning of white adipose tissue and
hypermetabolism. Treatment of adipocytes with sLR11 inhibits thermogenesis via the bone
morphogenetic protein/TGFb signalling pathway and reduces Smad phosphorylation. In
addition, sLR11 levels in humans are shown to positively correlate with body mass index and
adiposity. Given the need for tight regulation of a tissue with a high capacity for energy
wastage, we propose that LR11 plays an energy conserving role that is exaggerated in states of
obesity.
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M
urine studies have demonstrated that increasing heat
production in brown adipose tissue (BAT) can offset
obesogenic effects of a high-fat diet (HFD)1,2, whereas
reducing thermogenesis exacerbates them3. The existence of BAT
in adult humans has been ‘reconﬁrmed’ by using modern imaging
techniques and tissue biopsies4–6, increasing the importance of
understanding BAT’s physiological regulation. In addition, levels
of detectable BAT correlate negatively with age, body mass index
(BMI) and diabetes7, and using intermittent cold exposure to
increase amounts of BAT is sufﬁcient to increase post-prandial
energy expenditure and improve insulin sensitivity8. Collectively,
these ﬁndings support the hypothesis that thermogenesis in BAT
is an important factor contributing to human metabolism.
Numerous secreted and circulating factors have been identiﬁed
to date with the ability to enhance the amount and/or activity of
BAT9. Given the need for tight regulation of a tissue with such a
high capacity for energy wastage, it is somewhat surprising that
comparatively few negative regulators have been described.
Changes in levels of LR11 in humans have primarily been
associated with Alzheimer’s disease, linked to its potential role in
amyloid processing in the brain10. More recently, LR11 has been
shown to possess the required properties of a functional
lipoprotein receptor and the soluble form (sLR11) has been
shown to facilitate increased vascular smooth muscle cell
migration in response to injury, hinting at an equally important
peripheral role11–13. LR11 has also been shown to regulate
lipoprotein lipase (LPL), a key enzyme regulating the supply of
lipid to BAT, by coordinating both its anterograde and retrograde
vesicular transport14,15.
Here we show that mice lacking LR11 are protected from diet-
induced obesity because of a hypermetabolic phenotype,
facilitated by enhanced thermogenic gene expression in white
adipose tissue (WAT) depots. Our data demonstrate that sLR11 is
able to bind to bone morphogenetic protein (BMP) receptors and
suppress thermogenic signalling via suppression of downstream
Smad protein phosphorylation. The expression proﬁle of Lr11
and serum levels of sLR11 in mice increase at times of increased
thermogenesis, suggesting a regulatory role of sLR11 in prevent-
ing excessive energy wastage. sLR11 levels correlate with adiposity
in humans, leading us to conclude that sLR11 may be an
important negative regulator of adipose tissue energy expendi-
ture, which is dysregulated in obesity, potentially compromising
metabolic responses to nutritional stimuli.
Results
Lr11 / mice are hypermetabolic and protected from obesity.
We previously generated a mouse lacking LR11 to examine its
role in vascular smooth muscle cells in vivo and that of the
cleaved soluble form (sLR11) in vitro11,16. These studies
highlighted a tendency for Lr11 / mice to be lighter than
their wild-type (WT) littermates, and as such our central
hypothesis was that LR11 was in some manner acting as a
negative regulator of metabolism. To formally assess differences
in body weight, WT and Lr11 / mice were fed standard chow
or HFD to maximally expose differences in weight gain. The body
weight of WT 8-weeks-old mice on chow diet was similar to those
of Lr11 / mice; however, the size of the retroperitoneal and
reproductive fat pads were signiﬁcantly reduced (Table 1). In
contrast, HFD-fed Lr11 / mice had markedly lower body
weights than WT controls, a large portion of which was
accounted for by reductions in the weights of WAT and liver
(Table 1 and Supplementary Table 1). Reduced adiposity after 8
weeks of HFD was clearly evident from anatomical examinations
(Fig. 1a–f) and histological analyses revealed that Lr11 / mice
had smaller lipid droplets in BAT (Fig. 1e) and were protected
from hepatic steatosis (Fig. 1f). Analysis of weekly energy balance
on chow diet conﬁrmed no signiﬁcant difference in rate of body
weight change or daily food intake in 10–11-week-old mice
(Fig. 1g–i). Longer term monitoring of weight change in a
separate study indicated a clear increase in weight gain in WT
mice fed a HFD, with a high rate of divergence from the
persistently lean Lr11 / mice observed by the comparative
10-weeks-old time-point (Fig. 2a). Averaged daily food
intakes over the course of this study again conﬁrmed
no difference between genotypes (WT¼ 59.9±1.1,
Lr11 / ¼ 60.5±1.2 kJ day 1) or HFD (WT¼ 70.1±3.8,
Lr11 / ¼ 70.1±2.9 kJ day 1). We hypothesized that
increased energy expenditure was facilitating the reduction in
the rate of weight gain in Lr11 / mice fed HFD. Assessment of
energy expenditure using indirect calorimetry conﬁrmed that
Lr11 / mice had a higher metabolic rate than WT mice when
fed HFD (30±0.4 vs 27.5±0.3 Jmin 1) (Fig. 2b,c). Lr11 /
mice also displayed improved serum biochemistry proﬁles, with
lower fasting glucose, insulin and triglyceride levels, particularly
on HFD (Fig. 2d–f). Other circulating factors such as free-fatty
acids, T4, leptin and serum cholesterol were not signiﬁcantly
altered (Fig. 2g–k), nor were any signiﬁcant alterations in LPL
activity observed in Lr11 / tissues (Fig. 2l).
Lr11 / mice have increased thermogenic markers in WAT.
LR11 is known to have a predominantly neuronal expression
proﬁle17. However, analysis of Lr11 mRNA expression in WT
adipose tissue revealed similar levels to those found in brain, with
real-time quantitative PCR ct values of 26.9±4.1 in brain versus
26.6±0.6 in BAT and 28.7±0.8 in subcutaneous WAT (scWAT)
(n¼ 8). We therefore examined whether phenotypic changes in
Table 1 | Tissue weights from wild-type and Lr11  / mice.
Body (g) Reproductive
fat pad (g)
Inguinal
fat pad (g)
Retroperitoneal
fat pad (g)
Heart (g) Liver (g) Kidney (g)
Tissue weights from group housed mice fed standard chow diet (age¼ 8 weeks, n¼ 10)
WT 23.8±1.9 0.37±0.05 0.29±0.03 0.12±0.01 0.13±0.01 1.14±0.19 0.29±0.03
Lr11 / 21.56±1.34 0.24±0.02 0.27±0.04 0.05±0.01 0.13±0.01 1.23±0.07 0.31±0.06
% of wild type 91 64 94 38 100 108 106
Tissue weights from group housed mice fed high-fat (60%) diet from 8-weeks-old mice (age¼ 12 weeks, n¼ 10)
WT 34.13±4.53 2.19±0.45 1.77±0.26 0.81±0.15 0.13±0.01 1.43±0.17 0.33±0.02
LR11 / 23.63±4.21 0.95±0.46 0.84±0.36 0.24±0.12 0.13±0.01 0.92±0.25 0.32±0.01
% of WT 69 43 47 30 100 64 96
WT, wild type.
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adipose tissue may be driving the metabolic shift observed in
Lr11 / mice. Reduced lipid content in Lr11 / BAT on HFD
(Fig. 1e) suggested that the tissue was more metabolically, and
thus thermogenically, active. Examination of scWAT revealed
smaller, less lipid replete adipocytes (Fig. 3a), suggesting either
reduced lipid storage or increased lipid oxidation. Previous
studies have shown that scWAT has a high propensity for
‘browning’ in response to pharmacological and nutritional
signals18. Therefore, we performed immunostaining, which
conﬁrmed signiﬁcantly higher levels of uncoupling protein 1
(UCP1) than in WT tissue (Fig. 3b). Microarray analysis of gene
expression revealed signiﬁcant increases in thermogenic genes,
particularly in Lr11 / versus WT scWAT (Supplementary
Table 2). Based on histological and microarray data we
hypothesized that increased thermogenesis in adipose tissue
could explain the increase in metabolic rate in Lr11  / mice.
Increased expression of known key thermogenic factors was
conﬁrmed using quantitative PCR with reverse transcription,
including BMP 8b (Bmp8b), which we have previously shown to
be an important regulator of diet-induced thermogenesis
(Fig. 3c)3. Similar gene expression changes were observed in
canonical BAT, albeit to a lesser extent (Fig. 3d), likely because
of the already high levels of thermogenic gene expression
making detection of further modest increases more difﬁcult.
Other VPS10p or low-density lipoprotein receptor gene
family receptors such as Sortilin 1 (Sort1) and low-density
lipoprotein receptor related protein 1 (Lrp1) did not display any
signiﬁcant compensatory regulation in either scWAT or BAT
(Fig. 3c,d). No changes to markers of vascular endothelial cells
or the smooth muscle cell marker, alpha actin 2 (Acta2), were
detected in either BAT or subcutaneous WAT of Lr11 /
mice (Fig. 3e,f).
Lr11 / mice are more thermogenic following high-fat diet.
Increased thermogenic gene expression in Lr11 / mice fed an
HFD, coupled with the reduced body weight suggested that
Lr11 / mice may have increased diet-induced thermogenesis.
To functionally address changes in thermogenic capacity
in response to increased energy availability, we assessed the
thermogenic capacity of Lr11 / mice in response to HFD. To
eliminate any effect of environmental temperature, mice were
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Figure 1 | Lr11  / mice display reduced adiposity when fed a HFD. (a) Representative images of body size, (b) intra-abdominal fat, (c,d) separate white
adipose depots and (e) brown adipose tissue and (f) livers with haematoxylin and eosin staining of histological sections from mice fed HFD from 8 to 16
weeks of age; scale bars, 200mm. (g) Body weight, (h) change in body weight and (i) energy consumed in WTand Lr11  / mice over the course of 1 week
being fed standard chow while single housed, n¼ 5, data represented as means±s.e.m. (see also Table 1 and Supplementary Table 1).
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housed at thermoneutrality (30 C) while being fed HFD for 8
weeks before measurement. In this setting, any alterations to
maximum thermogenic capacity are driven by diet alone and
dependent on functional BAT, as demonstrated previously using
mice lacking Ucp1 (ref. 19). Lr11 / mice showed a greater
increase in energy expenditure from baseline in response to
norepinephrine (NE) injection compared with WT littermates,
corresponding to B12 Jmin 1 (Fig. 4a,b). This demonstrated
that HFD-fed Lr11 / mice had increased BAT recruitment and
thermogenic adaptation to HFD.
sLR11 inhibits O2 consumption in brown adipocytes. Based on
the thermoneutral HFD study data we hypothesized that a lack of
LR11 allowed animals to mount a disproportionately high
thermogenic response to increased sympathetic nervous system
stimulation following an increase in caloric intake. Primary
brown adipocytes (which normally have high endogenous
thermogenic capacity) from WT and Lr11 / mice were
cultured and differentiated in the presence or absence of puriﬁed
sLR11 (ref. 20). Functional thermogenic capacity was assessed by
NE-induced cellular respiration, as NE is the major signal from
the sympathetic nervous system that stimulates thermogenesis in
brown adipocytes21. Differentiated WT and KO adipocytes
showed similar basal respiration levels but primary adipocytes
from BAT of Lr11 / mice showed a greater response to NE
stimulation compared with cells from WT mice (Fig. 4c).
Conversely, treatment of Lr11 / cells with sLR11 almost
completely ablated the enhanced effect of NE stimulation on
oxygen consumption (Fig. 4d) and sLR11 signiﬁcantly reduced
lipolysis in WT brown adipocytes, as indicated by glycerol release
in response to maximum stimulation with NE (Fig. 4e). Opposite
to tissues lacking LR11, sLR11 treatment of WT primary brown
adipocytes resulted in a signiﬁcant reduction in expression of
multiple genes essential for thermogenesis, including Ucp1, Pgc1b
and b3 adrenergic receptor (Adrb3) (Fig. 4f).
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Figure 2 | Lr11  / mice are hypermetabolic with improved serum biochemistry. (a) Growth curves of wild-type and Lr11  / mice fed chow and HFD
from 8 to 16 weeks. (b) Indirect calorimetry expressed as a scatter plot showing the correlation between energy expenditure and body weight for single-
housed, 12-week-old wild-type (R2¼0.75) and Lr11 / (R2¼0.74) mice fed HFD (60% fat) from 8 to 16 weeks; and in (c) also expressed as an adjusted
mean energy expenditure for an adjusted mean body weight of 29.29 g, P-value obtained using analysis of covariance, n¼ 8–11. (d) Fasting glucose,
(e) fasting insulin, (f) fasting serum triglycerides following 8 weeks of diet administration from 8–16 weeks old. (g) Fasting free-fatty acids following 1 and 4
weeks of HFD from 8-weeks-old mice and (h–k) serum measurements of hormones and lipids in 16-week-old male wild-type and Lr11  / mice fed HFD
from 8 to 16 weeks, n¼ 5–6. (l) Lipoprotein lipase activity in conditioned media from mature adipocyte cultures from murine BATof WTand Lr11 / mice,
using free-fatty acid production as a readout (n¼ 3–4). Data are presented as means±s.e.m. w, z and # denote signiﬁcant effect of genotype,
diet and genotype*diet interaction respectively, obtained using 2-way ANOVA. (See also Supplementary Table 2). FFA, free-fatty acid.
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sLR11 inhibits thermogenesis via the BMP/Smad pathway.
Bmp7 and its downstream signalling cascade, which requires
phosphorylation of Smad proteins, has been identiﬁed as a key
mechanism regulating the formation of BAT and recruitment of
‘beige’ adipocytes within WAT22–25. To examine whether LR11
was interacting with this mechanism to regulate the observed
browning of scWAT, we differentiated primary adipocytes from
scWAT of WT and Lr11 / mice in the presence of
recombinant BMP7. BMP7 is a known driver of thermogenic
development and, as a member of the TGFb superfamily, signals
through BMP receptors (BMPR) to increase phosphorylation of
intracellular Smad proteins25. Cells lacking LR11 displayed a
signiﬁcantly greater increase in thermogenic gene expression in
response to BMP7, and this response was completely blocked in
cells of both genotypes by treatment with sLR11 (Fig. 5a–c).
Phosphorylation of Smads 1, 5 and 8 following BMP7 treatment
of primary adipocytes was also greatly reduced by sLR11
co-treatment (Fig. 5d). sLR11 treatment was also blocked
downregulation of the BMP receptor Bmpr1b, observed after
BMP7 treatment (Fig. 5e,f) and signiﬁcantly reduced
phosphorylation of SMAD3 in adipocytes following stimulation
with TGFb (Fig. 5g). Further evidence for the ability of sLR11 to
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directly inhibit the BMP signalling pathway was provided by an
immunoprecipitation assay, which showed that sLR11 was able to
bind BMPR1a and BMPR1b, but not BMPR2 (Fig. 5h). Finally,
reduced expression of either BMPR1a or BMPR1b in cultured
brown adipocytes was sufﬁcient to negate the repressive action of
sLR11 on Ucp1 expression (Fig. 5i).
The cytoplasmic domain of LR11 has also been shown to
function as a transcription factor26, leading us to test whether
LR11 could regulate the transcriptional activity of known
thermogenic response elements. Overexpression of LR11
resulted in a small but signiﬁcant reduction in transcription
driven by the Bmp8b promoter, a thyroid response element and
the Ucp1 promoter enhancer, but not by the Ucp1 core promoter
(Supplementary Fig. 1). We next examined the physiological
regulation of LR11 and found its gene expression to be regulated
in line with thermogenic activation, decreasing in both BAT and
scWAT as environmental temperature rose from cold to
thermoneutrality (Fig. 6a). Serum sLR11 levels followed the
same pattern, reaching their highest point at 5 C when
thermogenesis is maximally activated in mice (Fig. 6b). Lr11
mRNA was also regulated by changes to energy availability in a
pattern identical to thermogenesis, increasing in the fed state and
declining after fasting (Fig. 6c).
sLR11 levels correlate with BMI and adiposity in humans.
Finally, to test the relevance of our ﬁndings to human metabolism
and as LR11 is highly expressed in adipose tissue, we examined
the relationship between adiposity and sLR11 in two cohorts of
patients. In 156 subjects with sleep apnoea (Supplementary
Table 4), circulating sLR11 levels were positively correlated with
age, BMI, visceral (VFA) and subcutaneous fat areas (SFA), and
HbA1c and negatively correlated with smoking and high-density
lipoprotein (HDL) cholesterol (Fig. 6d–f and Table 2). Multiple
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regression analysis of these variables showed that sLR11 levels
were not signiﬁcantly associated with any of them but tended to
associate most with VFA, independently of other factors
(Table 2). A second study of 25 patients with type 2 diabetes
mellitus or glucose intolerance-associated metabolic disorders
(Supplementary Table 5) showed a similar signiﬁcant correlation
between BMI and sLR11 levels (Fig. 6g). Importantly none of the
other measured characteristics of these subjects, such as age,
HbA1c or cholesterol levels, showed any correlation with sLR11
(Supplementary Table 5). This further suggested that overall body
weight, and thus adiposity, was the major determinant of sLR11
levels in humans. In a third study of 14 obese patients who
underwent bariatric surgery, post-operative sLR11 levels were
signiﬁcantly reduced after 12 months, concomitantly with
reductions to BMI, VFA and SFA (Table 3). The percentage
reduction in sLR11 was positively correlated with that of VFA
and SFA (Fig. 6h,i). Multiple regression analysis of the two
signiﬁcant correlates, VFA and SFA, showed no signiﬁcance
between their respective contributions to the relationship
(Table 3), suggesting that overall fat mass, regardless of its
distribution, was driving the correlation.
Discussion
Our data demonstrate a role for sLR11 as a negative regulator of
thermogenesis, acting through the BMP/Smad pathway in
adipose tissue to suppress activation of thermogenic machinery
and inhibit transcription of key thermogenic genes. LR11 is
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Figure 6 | sLR11 levels are metabolically regulated and correlate with BMI and adiposity in humans. (a) Lr11 mRNA expression levels in tissues from 12-
week-old mice exposed to cold (5 C), room temperature (23 C) or thermoneutrality (30 C) for 3 weeks (n¼8) and (b) serum sLR11 levels in mice
housed under the same conditions (n¼4). (c) Lr11mRNA expression in BATand ScWAT from fed, 24 hr fasted and 24 h re-fed mice (n¼8), data presented
as mean±s.e.m., *¼ Po0.05 using one-way ANOVA followed by Tukey post-hoc test. (d) Serum sLR11 levels in patients with sleep apnoea correlated with
BMI, (e) VFA and (f) SFA (n¼ 156). (g) Serum sLR11 levels in patients with type 2 diabetes mellitus or glucose intolerance-associated metabolic disorders
correlated with BMI, (n¼ 25). (h) % reduction in serum sLR11 levels in 14 obese patients 12 months after bariatric surgery correlated with % reduction to
VFA and (i) SFA. Correlations evaluated using Pearson correlation (see also Tables 2 and 3). scWAT, subcutaneous white adipose tissue; gWAT, gonadal
adipose tissue.
Table 2 | Correlation between sLr11 levels and characteristics of sleep apnoea.
Single correlation with sLR11 levels Multivariate analysis of correlates
Factors r or mean±s.d. P b P
Age 0.169 0.035 0.034 0.084
Total cholesterol 0.039 0.626
Triglyceride 0.062 0.443
HDL-cholesterol 0.196 0.014 0.008 0.541
LDL-cholesterol 0.108 0.18
BMI 0.186 0.02 0.047 0.548
VFA 0.212 0.008 0.008 0.056
SFA 0.206 0.01 0.001 0.83
HbA1c 0.171 0.032 0.080 0.736
CAD, yes/no 9.72±2.91/10.43±2.98 0.175
CVD, yes/no 10.00±2.19/10.19±3.01 0.962
Sex, men/women 10.08±2.91/10.39±3.10 0.489
Smoking, yes/no 9.66±2.83/10.79±3.02 0.025 0.482 0.19
BMI, body mass index; CAD, coronary artery disease; CVD, cerebrovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SFA, subcutaneous fat areas; VFA, visceral fat areas.
Initial correlations derived using Pearson correlation test. Multiple regression analysis performed in patients to examine the seven characteristics more strongly correlated with sLR11 levels using beta
weights to detect signiﬁcant differences in the contribution of each factor, n¼ 156.
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regulated in tissues with inherent/adaptive thermogenic capacity,
in response to changes in environmental temperature and diet,
but not in other metabolic tissues such as liver (Fig. 6a). In
absence of any endogenous LR11, nutritional stimuli that induce
thermogenesis in scWAT are left unchecked, leading to increased
recruitment of brown adipocytes, reduced lipid accumulation,
hypermetabolism and overall leanness.
Our in vitro data support a cell-autonomous role of sLR11 in
regulating adipose tissue responses to increased energy avail-
ability. This is suggested by the peptide’s ability to suppress the
known thermogenic signalling pathways and the lack of any
signiﬁcant change to energy balance on a standard chow diet.
Neurological roles for LR11 have been previously described,
although we hypothesize that if LR11 is required to maintain a
central circuit regulating metabolic rate, it would be expected that
its ablation would yield a consistent phenotype across environ-
mental conditions. Instead metabolic rate changes only become
apparent in Lr11 / mice fed HFD, when sympathetic tone to
BAT and WAT depots increases and adaptive changes occur to
strike a new balance between lipid oxidation and storage. In the
absence of LR11 and thus sLR11, increased energy availability
results in increased DIT in adipose tissue but without the
appropriate anabolic response. Where WT mice are able to store
additional calories as triglyceride, Lr11 / mice can only
increase the metabolic arm of the response and burn them.
However, even on a chow diet there is a slight tendency for
Lr11 / mice to be lighter and consume slightly less food
(Fig. 1g–i and Fig. 2a) and it is also highly likely that DIT is itself
regulated by discrete neuronal pathways that mediate alterations
to sympathetic activation of thermogenic tissues. Therefore we
cannot rule out based on our current data, that LR11 may also
play a central role in the initiation and maintenance of metabolic
responses and energy balance.
LR11 has also been previously shown to increase vascular
smooth muscle cell migration in response to injury11. We did not
observe any alteration to vasculogenesis or angiogenesis in
Lr11  /mice, suggesting that perturbations in these processes
are not causative of the hypermetabolic phenotype. Similarly, the
documented ability of LR11 to regulate LPL activity15 was not
evident as a mechanism by which its deletion led to
hypermetabolism in our model (Fig. 2l). Our data also suggest
that sLR11 levels are dependent on adipose mass in humans,
increasing in line with fat mass. Clinical interventions such as
bariatric surgery that lead to reductions in adiposity, also lower
sLR11 levels (Table 3 and Fig. 6h,i), potentially contributing to
the observed increase in metabolic rate in such patients27,28. The
fact that the strongest correlation in all human subjects is between
sLR11 and visceral and SFA, rather than BMI is further evidence
that adipose tissue is the main site of sLR11 production and
secretion.
We identify LR11 as a key metabolic regulator, which functions
to maintain the adequate balance between lipid storage and
oxidation in response to changing environmental conditions and
particularly when thermogenic activity is increased in capable
tissues. This mechanism might be exploited for anti-obesity
therapies or conversely, for the treatment of conditions
such as anorexia nervosa or cachexia. The apparent anabolic
role of sLR11 may also be relevant for understanding its
prior implication in cardiovascular disease and Alzheimer’s
disease29,30. While an increasing number of factors and
pharmacological molecules exist that either increase the number
of brown adipocytes or their thermogenic capacity9,31, only a
small number of negative regulators are apparent, namely nuclear
receptor-interacting protein 140 (Rip140) and the diurnally
regulated Rev-erba (refs 32,33). It seems likely that other
negative regulators must exist to ensure effective control of this
energy-expensive mechanism and to ‘ﬁne tune’ the thermogenic
response. Before our study, a lipoprotein receptor-mediated
mechanism for regulation of BMP signalling in the regulation of
thermogenesis has not been described.
Methods
Animals and diets. Unless otherwise stated, all data are from work on males (8–16
weeks of age). C57Bl6/J mice were purchased from Charles River. Lr11 / mice
were generated as previously described11 on a C57Bl6/J background and compared
to WT littermates. Unless stated, mice were housed in a temperature-controlled
room (22 C) with a 12-h light/dark cycle with free access to diet and water.
Standard chow or HFD was administered ad libitum from weaning until indicated.
High-fat diet consisted of 60% calories from fat (D12492, Research Diets, NJ, USA)
unless otherwise stated. Thermoneutrality involved housing mice at 30 C in a
normal home cage environment. All animal procedures were approved by either
the UK Home Ofﬁce or the Special Committee on Animal Welfare, School of
Medicine, at the Inohana Campus of Chiba University.
Calculation of energy expenditure. Animals were placed in a monitoring system
based on their home cages (Creative Scientiﬁc, Canterbury, UK) with the ability to
measure oxygen and carbon dioxide concentrations using a system (Minimox)
designed by Peter Murgatroyd (University of Cambridge)34. Oxygen consumption
and carbon dioxide production was measured, with samples taken at 18min
intervals over a 48-h period. Energy expenditure was then calculated using indirect
calorimetry with the Elia and Livesey constant35. Energy expenditure is expressed
as Jmin 1 per mouse using an adjusted mean body weight. This was obtained
using analysis of covariance with weight as the covariate, a robust method for
Table 3 | Effect of bariatric surgery on adiposity and sLR11.
Characterization pre- and 12 month post-bariatric surgery (n¼ 14)
Factor Before After P % reduction
sLR11 16.79±7.03 ngml 1 10.36±4.84 ngml 1 0.001 37.6±11.9
BMI 44.37±8.64 31.43±5.41 0.001 28.3±9.7
VFA 245.30±135.44 cm2 96.84±57.44 cm2 0.001 57.7±20.9
SFA 651.23±439.63 cm2 356.50±129.76 cm2 0.001 37.1±20.5
Correlation with % reduction in sLR11 Multiple linear regression
95% CI 95% CI
r Lower Upper B Lower Upper
% reduction of BMI 0.422 0.140 0.778
% reduction of VFA 0.583 0.076 0.851 0.211 0.236 0.659
% reduction of SFA 0.561 0.043 0.841 0.165 0.292 0.622
BMI, body mass index; CI, conﬁdence interval; SFA, subcutaneous fat areas; VFA, visceral fat areas.
Changes to sLR11, BMI, VFA and SFA pre- and 12 months post-bariatric surgery with respective reductions (%). Data presented as means±s.d.; P values for each pre- and post-surgery comparison
determined using a paired sample Wilcoxon Signed-Rank test, n¼ 14. Contributions of factors to correlations with % reduction in sLR11 were assessed using multiple linear regressions.
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comparison of groups with divergent body weight and composition36. High-fat diet
consisting of 45% calories from fat (D12451, Research Diets, NJ, USA) was used for
the calorimetric study as the consistency of the 60% fat diet is not compatible with
the food hoppers in the measurement system.
Serum biochemistry. Murine serum triglycerides and glucose concentrations were
measured using Triglyceride E-test kit and glucose CII kit, respectively (Wako
chemicals, Osaka Japan), according to the manufacturer’s instructions. Serum
insulin levels were measured using ultrasensitive ELISA kit (Morinaga, Yokohama,
Japan) according to the manufacturer’s instruction.
Microarray. The four RNA sources, WT scWAT, Lr11 / scWAT, WT BAT and
Lr11 / BAT, were prepared from subcutaneous WAT and BAT from WT mice
and Lr11 / mice, respectively (n¼ 3 each). Microarray analyses were performed
by Takara Bio (Japan). Brieﬂy, cyanine-3-labelled cRNA was prepared from 0.1 mg
total RNA using the Low Input Quick Amp Labeling kit (Agilent) according to the
manufacturer’s instructions, followed by RNAeasy column puriﬁcation (QIAGEN,
Valencia, CA). Dye incorporation and cRNA yield were checked with the Nano-
Drop ND-2000 Spectrophotometer. An amount of 0.6 mg of cyanine-3-labelled
cRNA was then fragmented at 60 C for 30min in a reaction volume of 25 ml
containing 1 Agilent fragmentation buffer and 2 Agilent blocking agent fol-
lowing the manufacturer’s instructions. On completion of the fragmentation
reaction, 25ml of 2 Agilent hybridization buffer was added to the fragmentation
mixture and hybridized to Agilent Mouse GE 8x60K Microarray for 17 h at 65 C
in a rotating Agilent hybridization oven. After hybridization, microarrays were
washed 1min at room temperature with GE Wash Buffer 1 (Agilent) and 1min at
37 C GE Wash buffer 2 (Agilent), then dried immediately by brief centrifugation.
Slides were scanned immediately after washing on the Agilent DNA Microarray
Scanner (G2565CA) using one colour scan setting for 8 60 k array slides (scan
area 61 21.6mm, scan resolution 3 mm, dye channel is set to Green PMT to
100%). The scanned images were analysed with Feature Extraction Software 10.10
(Agilent) using default parameters to obtain background-subtracted and spatially
detrended processed signal intensities. The gene-tree analysis revealed six clusters
based on the expression pattern of the four RNA sources. The gene expression
pattern with Cluster 6: WT scWAToLr11 / scWAToor¼WT BAT¼
oroLr11 / BAT was dominant compared with other patterns. The top 100
genes of Lr11 / scWAT4WT scWAT in cluster 6 were listed and summarized
(Supplementary Table 2).
Quantitative PCR with reverse transcription. Total RNA was isolated from cells
or using Buffer RLT and puriﬁed by RNeasy Mini columns (Qiagen). RNA was
isolated from ground tissues using STAT-60 reagent (TEL-TEST) followed by
chloroform extraction and isopropanol precipitation. Complimentary DNA was
generated from 500 ng of RNA using M-MLV reverse transcriptase and master mix
(Promega) in a 20 ml reaction mixture with 2.5mM MgCl2, 1.25mM dNTPs and
5 mgml 1 random hexamers at 37 C for 1 h. Complementary DNA was diluted
75-fold and 5 ml of diluted complementary DNA was used in a 12 ml real-time PCR
reaction mixture using TaqMan primers and probes or SYBR green reagent
(Applied Biosystems) according to manufacturer’s instructions. Reactions were run
in duplicate for each sample and quantiﬁed in the ABI Prism 7900 sequence
detection system (Applied Biosystems). Data are expressed as arbitrary units where
expression of target genes are corrected using the geometric average of four
housekeeping genes: 18S, b2-microglobulin, b-actin and 36B4 using Bestkeeper
(freeware). Sequences of primers and probes used are listed in Supplementary
Table 3.
Tissue collection and histology. All animal tissues for protein or RNA extraction
were snap frozen in liquid nitrogen at the time of collection unless otherwise stated
and later ground to a ﬁne powder using a sterile pestle and mortar on liquid
nitrogen. Samples for histology were placed in 10% buffered formalin overnight
before transfer to 70% ethanol and later embedding in parafﬁn. Multiple sections
were stained with haematoxylin and eosin for morphological analysis.
Immunohistochemistry. Parafﬁn-embedded sections (5 mm) were used for
immunohistostaining. Deparafﬁnized sections were pretreated with 0.3% H2O2 to
inactivate endogenous peroxidase. Slides were stained in the presence of 3% bovine
serum albumin (BSA) with antibody against UCP1 (1:50 dilution) at 23 C for1 h
followed by horseradish peroxidase-conjugated anti-rabbit IgG secondary anti-
bodies (Molecular Probes) at 1:200 dilution. The slides were counterstained with
haematoxylin. Controls with non-immune rabbit IgG were conducted in parallel
with each immunoassay procedure.
Western blot. Powdered tissue or collected cultured cells were resuspended in
lysis buffer (20mM Tris-HCL, 150mM NaCl, 1mM EGTA, 1mM EDTA, 1%
Triton X-100, pH7.5) with added protease and phosphatase inhibitor cocktails
according to manufacturers instruction (Sigma). After lysis, lysates were cleared by
centrifugation at 10 000g for 10min at 4 C. Protein concentrations of the
supernatants were determined by Dc Protein assay (Bio-Rad). Proteins were diluted
in Laemmli buffer with 1% 2-mercaptoethanol. Proteins (20 mg) were separated by
SDS–polyacrylamide gel (10%) electrophoresis and transferred to Immobilon-P
membrane using a semi-dry transfer apparatus (Biorad). Membranes were blocked
for 1 h at room temperature and incubated overnight at 4 C with the indicated
antibody. Bound primary antibodies were detected using peroxidase-coupled sec-
ondary antibodies and enhanced chemiluminescence (Amersham). Relative
quantiﬁcation of band intensities was calculated by digitally photographing
exposed ﬁlms and using Genesnap and Genetools software (Syngene). Uncropped
scans of blots are shown in Supplementary Fig. 2.
SMAD assays. Cultured fully differentiated adipocytes derived from the sub-
cutaneous fat tissues of wild-type or Lr11 / mice in the presence of BMP7 for
the ﬁrst 2 days were prepared. After serum depletion for 16 h, the cells were
incubated with or without 3.3 nM BMP7 or 2 ngml 1 TGF-b in the presence or
absence of 10 ngml 1 sLR11 for 30min, and then collected for the following
western blot analyses. Cells were washed three times with phosphate-buffered
saline (PBS) and harvested in RIPA buffer containing 0.01mM APMSF. For
immunoblotting, equal amounts of solubilized protein was subjected to 10%
SDS polyacrylamide gel after heating to 95 C for 5min under reducing condi-
tions and transferred to a nitrocellulose membrane.
Immunoprecipitation. An amount of 100 mg of membrane protein was mixed with
1 mg of anti-human LR11 antibody M3 or control IgG, and rotated for 1 h at 4 C.
The LR11/BMPRs/antibody complex was precipitated by protein A Sepharose. The
proteins were released into 25 ml SDS sample buffer by heating to 95 C for 10min,
and applied for western blot analysis using anti-BMPR1A, BMPR1B or BMPR2
antibody as described.
Antibodies and recombinant and puriﬁed proteins. Monoclonal antibodies
against phospho-SMAD1/5/8 (#9511, Lot#14, 1:1,000), SMAD3 (#C25A9, Lot#13,
1:1,000) and BMPR2 (#6979, Lot#1, 1:1,000) were obtained from Cell Signaling.
Monoclonal antibodies against BMPR1A (MAB2406, Lot#UEJ0112071, 1 mgml 1)
and BMPR1B (MAB505, Lot#DGD0410091, 1 mgml 1) were obtained from R&D
Systems. Monoclonal Antibody to b-Actin was obtained from Sigma Aldrich
(#A2228, Lot#052M4816V, 1:1,000). Rabbit polyclonal antibody against UCP1 was
obtained from Abcam (ab23841, Lot#GR34748-1, 5 mgml 1). Recombinant
human BMP7 (354-BP, Lot#EOS1914031, 3 nM l 1) was obtained from R&D
Systems. Soluble form of LR11 protein (sLR11) was puriﬁed from the medium
incubated with Colo201 (B226, JCRB Cell Bank, Osaka, Japan) by afﬁnity column
using monoclonal antibody against sLR11, followed gel ﬁltration as previously
described20. Puriﬁed sLR11 was concentrated and used for experiments at a
concentration of 10 ngml 1, estimated from its biological activity in stimulating
the migration of smooth muscle cells as previously described11.
Culture of adipocytes. Mouse primary adipocytes were obtained from either BAT
or subcutaneous WAT by excision of the fat pad followed by mincing with sterile
surgical scissors and digestion at 37 C with shaking for B35min (10ml Hanks
buffered salt solution, 2% BSA, 2mgml 1 Type 2 collagenase (C6885, Sigma).
Digests were ﬁltered through a 100 mM ﬁlter and left to sit on ice for 10min. The
upper fat layer was removed and then the upper 2/3 of the supernatant washed
twice in PBS before being plated. Cells were maintained and differentiated in
Dulbecco’s modiﬁed Eagle’s medium with 10% fetal bovine serum, 20mM L-glu-
tamine, 100 units ml 1 penicillin and 100 mgml 1 streptomycin with 150 mM
sodium ascorbate and 4 nM insulin in the presence of 1 nM 3, 30 , 5-Triiodo-L-
thyronine at 37 C in 5% CO2. After 8 days, cells were fully differentiated (validated
by gene expression proﬁles and morphological appearance), and if BMP7 and/or
sLR11 were added, 3.3 nM BMP7 was present in the culture media for the ﬁrst 2
days and/or 10 ngml 1 sLR11 was present throughout the culture period. Cultures
were routinely tested for the presence of mycoplasma contamination and decon-
tamination/rederivation performed when necessary. Human primary preadipocytes
were prepared from the stromal vascular fraction of fat tissues and cultured as
described37. The procedures were approved by the Ethical Committee on human
study, Toho University Sakura Medical Center.
Transfection of cultured brown adipocytes with siRNA. Cultured brown adi-
pocytes were transfected with siRNA (25 nM) speciﬁc for BMPR1A (L-040598-00-
0005, Dharmacon, GE healthcare) or BMPR1B (L-051071-00-0005, Dharmacon),
or with control siRNA (D-001810-10-05, Dharmacon) for 3 days according to
manufacturer’s instruction protocol (https://dharmacon.gelifesciences.com/uploa-
dedFiles/Resources/basic-dharmafect-protocol.pdf) for the siRNA transfection
reagent (T-2001-01, Dharmacon), and then incubated with differentiation media
for mature brown adipocytes for 2 days. After serum depletion for 16 h, the cells
were incubated with or without sLR11 at 10 ngml 1 for 2 h, and used for real-time
PCR analyses.
Cell lines. Hek 293 cells were obtained from Sigma (product number 85120602).
While cells were not independently authenticated, this was not a major concern as
they were used only for the luciferase reporter assays and have been routinely used
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in our laboratory for multiple previous similar experiments without problems.
Grossly the cells behaved as expected in terms of their growth and morphology and
their viability and transfection efﬁciency were found to be excellent. As for primary
cultures, cultures were routinely screened for mycoplasma contamination.
LPL activity assay. This assay was performed as previously described38. Brieﬂy,
the culture medium for adipocytes cultured for 16 h without fetal bovine serum
were collected and the LPL activity was measured as below using triolein (Sigma,
St Louis, MO) as the substrate. The substrate solution was prepared as follows:
100mg of triolein and 7.5ml of 0.2% Triton X-100 at a ﬁnal volume of 7.5ml of
1mole l 1 Tris-HCl (pH 8.0) were sonicated on ice for 10min. The LPL activity
assay reaction mixture contained 50 ml of substrate solution, 25 ml of 20% fatty acid-
free bovine serum albumin (pH 8.0; Sigma), 5 ml of HDL (3mg proteinml 1) as a
source of apo C-II and 100 ml of sample. After incubation for 2 h at 37 C, the
enzyme reaction was terminated by the addition of 10 ml of di-
isopropylﬂuorophosphate. The amount of free-fatty acids released in the mixture
was measured at 4 C using an enzymatic method (Nescauto NEFA V2; Alfresa
Pharma, Osaka, Japan).
Cellular respiration. Differentiated primary adipocytes were placed in a XF24
bioanalyser (Seahorse Bioscience, MA, USA) in the manufacturer’s designated
culture/assay plate (each plate was seeded with an equal number of cells from a
pool of primary adipocytes from two animals). Basal cellular respiration was
measured over a period of 15min using the oxygen consumption rate (OCR)
measurement assay template. An amount of 100 nM NE was then added to the
assay medium (XF assay medium, Seahorse) and respiration measured for a further
15min using OCR measurement template. Basal and stimulated oxygen con-
sumptions reported are the mean of three separate OCR measurements per well.
NE-induced thermogenesis. Two individually housed mice (litter mates) were
monitored simultaneously at an airﬂow of 1 lmin 1. HFD-fed mice housed at
thermoneutrality for 8 weeks before assessment were anaesthetized with pento-
barbital (45mg kg 1 i.p.). The oxygen consumption and carbon dioxide production
of the mice was measured at 30 C to obtain basal values during 15min. Thereafter
the mice were removed from the metabolic chambers for 6min and injected sub-
cutaneously with NE (1mg kg 1) before being returned to the metabolic chambers
for 45min. Energy expenditure was calculated as described above but presented as
the fold increase or mean increase, thus not requiring covariate analysis.
Clinical study. Study 1 subjects consisted of 156 consecutive patients with sleep
apnoea syndrome and study 2 consisted of 25 consecutive patients with type 2
diabetes mellitus or glucose intolerance-associated metabolic disorders at Toho
University Sakura Medical Center or Yanbian University Hospital. Blood samples
were collected in the morning after an overnight fast, and the biochemical data
were measured using standard hospital laboratory techniques. The potential risk
factors for diabetes and atherosclerosis were analysed, including age, sex, BMI,
VFA and SFA, blood lipids and HbA1c for both studies; smoking, medication of
diabetes, medication of hypertension, medication of dyslipidemia, history of cor-
onary artery disease and history of cerebrovascular diseases for Study 1; fasting
plasma glucose and systolic and diastolic blood pressures for Study 2. In Study 3, 14
obese subjects received bariatric surgery at Toho University Sakura Medical Center,
and their VFA and SFA were measured before and 12 months after the surgery.
The body weights of all patients decreased 1 year after surgery compared with those
before surgery. Visceral fat areas and SFA were measured at umbilical levels of
patients using computed tomography. Hypertension was deﬁned as systolic pres-
sure of more than 140mmHg or diastolic pressure of more than 90mmHg.
Diabetes mellitus was deﬁned as a fasting blood glucose level of more than
126mg dl 1, glycosylated haemoglobin (HbA1c) of more than 6.2%, or both.
Dyslipidemia was deﬁned as serum total cholesterol of more than 220mg dl 1 and
triglycerides of more than 150mg dl 1 in the fasting state, or both, and HDL
cholesterol o40mg dl 1, or a combination thereof. The patients suffering from
possible malignant diseases, Alzheimer’s disease, renal diseases or hepatic diseases
were excluded in the study subjects. The procedures of the above human studies
were approved by the Human Investigation Review Committee on human study,
Toho University Sakura Medical Center or Yanbian University Hospital. Informed
consent was obtained from all subjects.
sLR11 measurement. Serum sLR11 concentrations were determined using a
sandwich ELISA system. 12.5 ml of human and 2.5 ml of murine serum were used
for the measurement of sLR11 by respective ELISA. Human serum sLR11 con-
centrations were determined using a revised procedure based on sandwich ELISA
system previously reported39. In brief, 12.5 ml of human serum were diluted eight-
fold with 1% BSA in PBS containing 0.1% Tween 20 (PBST), reacted with the
capture anti-LR11mouse monoclonal antibody M3 F(ab0)2 for 2 h, then incubated
with a biotinylated capture anti-LR11 rat monoclonal antibody R1 for 1 h. A
murine serum soluble LR11 ELISA was performed using two mouse monoclonal
antibodies, Mab93222 and Mab93213 that were established by immunization of
Lr11 / mice using synthetic peptides against different epitopes of VPS10p
domain of LR11 protein40. Brieﬂy, 2.5 ml of murine serum were diluted 20-fold with
1% BSA in PBST, reacted with the capture Mab93222 for 2 h, and then incubated
with the biotinylated capture Mab93213 for 1 h. The LR11-antibody complex was
quantiﬁed with horseradish peroxidase-conjugated streptavidin using puriﬁed
human and rabbit LR11 protein as a standard.
Power calculations. Group sizes were calculated using STPLAN software created
by Barry Brown from the University of Texas MD Anderson Cancer Center. We
have used mean values and standard deviations obtained from preliminary data
from studies in Lr11 / mice. In this instance we expected effect sizes ranging
down to 30% and aimed to obtain statistical signiﬁcance of Po0.05 at a power of
0.9. With the expected s.d. of up to 12% and thus planned to include a minimum of
seven animals/group for in vivo studies.
Exclusion criteria. Animals were excluded if their phenotypic characteristic fell
more than two s.d. from the mean of the group. In practice only two animals were
excluded from two separate parts of this study.
Randomization and blinding. No formal randomization was applied, but for diet
studies, animals of each genotype were grouped so as to match mean starting
bodyweights of chow and HFD groups. The researchers were not blinded as to the
genotype of the animals as this was not practical because of the weight divergence
phenotype. All measurement of gene expression and serum biochemistry was
conducted by a researcher who was blinded for the experimental groups’ identities.
Statistics. Statistical analysis was performed with SPSS statistics version 23 (IBM)
or Stat Flex v. 5.0 (Artech). Data was tested for normality and a Levene test for
equality of variance was also applied to all data sets before parametric tests were
applied. P values were not applied to exploratory initial studies where only the null
hypothesis was being tested, only where an a priori hypothesis had been deﬁned
and informed the study. Associations of sLR11 levels with risk factors were
examined by Pearson correlation analysis for continuous variables and by unpaired
t-test for categorical variables between groups (sex, smoking, medication of dia-
betes, hypertension or dyslipidemia and history of coronary artery disease or
cerebrovascular disease). The study subjects were principally separated to two
groups based on the averaged values. In clinical studies, multiple linear regression
analyses were used to calculate coefﬁcient beta for sLR11 by controlling for age,
smoking, HDL-cholesterol, HbA1c, BMI, VFA and SFA for study 1, and VFA and
SFA for the study of patients that received bariatric surgery (study 3), which are
signiﬁcantly correlated with sLR11.
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